Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8448417 | 0.90 | ESR1 (0.45) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL28875175 | 0.89 | TDP1 (0.68) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL51601 | 0.89 | TDP1 (0.68) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL395809 | 0.89 | KDM4E (0.58) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| Ethylene Glycol SCHEMBL15661698 | 0.83 | ALDH1A1 (0.62) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL7715544 | 0.82 | GAA (0.50) | KMT2AALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL4570317 | 0.82 | TDP1 (0.59) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL9817384 | 0.82 | TDP1 (0.59) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL21953404 | 0.81 | TDP1 (0.67) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL393791 | 0.81 | MAPT (0.47) | MAPK1KMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5401868-A | Sulfiding and esterification to form chemical intermediates | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUCTIONSAKTIESELSKAB) (DK) | 1995-03-28 | — | — | US | claimed |
| EP-0541550-B1 | NEW INTERMEDIATES, THEIR PRODUCTION AND USE | LEO PHARM PROD LTD (DK) | 1994-09-07 | — | — | EP | claimed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0627942-B1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1999-09-15 | — | — | EP | disclosed |
| US-5795562-A | BIODEGRADABLE POLYMER AS CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | NYCOMED IMAGING AS (NO) | 1998-08-18 | — | — | US | disclosed |
| US-5676925-A | USING POLYESTER OR ACRYLATE POLYMERS | NYCOMED IMAGING AS (NO) | 1997-10-14 | — | — | US | disclosed |
| US-5674468-A | A BIODEGRADABLE POLYESTER; USEFUL IN DIAGNOSTIC APPLICATIONS SUCH AS ULTRASOUND AND MAGNETIC RESONANCE IMAGING | NYCOMED IMAGING AS (NO) | 1997-10-07 | — | — | US | disclosed |
| US-5574097-A | NONCROSSLINKED POLYMERS WITH BIODEGRADABLE LIPOPHILIC SIDE CHAINS INCORPORATING METHYLENE DIESTER UNITS, CLEAVABLE TO YIELD A WATER SOLUBLE POLYMER | NYCOMED IMAGING AS (NO) | 1996-11-12 | — | — | US | disclosed |
| EP-0629214-B1 | CHEMICAL COMPOUNDS | NYCOMED IMAGING AS (NO) | 1996-10-23 | — | — | EP | disclosed |
| EP-0629214-A1 | CHEMICAL COMPOUNDS. | NYCOMED IMAGING AS (NO) | 1994-12-21 | — | — | EP | disclosed |
| EP-0627942-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993017718-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING A/S (NO) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993018070-A1 | CHEMICAL COMPOUNDS | NYCOMED IMAGING AS (NO) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | TDP1 4317/4885MAPK1 3726/4885HIF1A 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.